Considerations for payers in managing hormone receptor-positive advanced breast cancer

References

• ForouzanfarMHForemanKJDelossantosAMBreast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysisLancet201137898011461148421924486
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyBreast Cancer Facts and Figures: 2011–2012Atlanta, GAAmerican Cancer Society2012 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdfAccessed December 18, 2013
   Google Scholar
• American Cancer SocietyCancer facts and figures 2014Atlanta, GAAmerican Cancer Society2014 Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdfAccessed June 13, 2014
   Google Scholar
• CardosoFSenkus-KonefkaEFallowfieldLCostaACastiglioneMESMO Guidelines Working GroupLocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v15v1920555067
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [homepage on the Internet]SEER Statistic Fact Sheet: Breast Cancer2013 Available from: http://seer.cancer.gov/statfacts/html/breast.htmlAccessed December 18, 2013
   Google Scholar
• MariottoABYabroffKRShaoYFeuerEJBrownMLProjections of the Cost of Cancer Care in the U.S.: 2010–2020J Natl Cancer Inst2011103211712821228314
   PubMed Web of Science ®Google Scholar
• SetiawanVWMonroeKRWilkensLRKolonelLNPikeMCHendersonBEBreast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort studyAm J Epidemiol2009169101251125919318616
   PubMed Web of Science ®Google Scholar
• AndersonWFChatterjeeNErshlerWBBrawleyOWEstrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results databaseBreast Cancer Res Treat2002761273612408373
   PubMed Web of Science ®Google Scholar
• CleatorSJAhamedECoombesRCPalmieriCA 2009 update on the treatment of patients with hormone receptor-positive breast cancerClin Breast Cancer20099Suppl 1S6S1719561006
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology. Breast Cancer. version 3.2014. NCCN Web site http://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed June 9, 2014
   Google Scholar
• Arimidex (anastrozole tablets) [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2013
   Google Scholar
• Femara (letrozole tablets) 2.5 mg tablets [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2011
   Google Scholar
• Aromasin (exemestane tablets, oral) [prescribing information]New York, NYPharmacia and Upjohn Company2013
   Google Scholar
• Faslodex (fulvestrant) injection [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2012
   Google Scholar
• Nolvadex (tamoxifen citrate tablet) [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2007
   Google Scholar
• Afinitor (everolimus) tablets for oral administration [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2014
   Google Scholar
• ReimbursementCodes [homepage on the Internet]Rocky Hill, CTRJ Health Systems ReimbursementsCodes Available from: http://reimbursementcodes.com/Accessed December 18, 2013
   Google Scholar
• JohnstonSRNew strategies in estrogen receptor-positive breast cancerClin Cancer Res20101671979198720332324
   PubMed Web of Science ®Google Scholar
• Harichand-HerdtSZelnakAO’ReganREndocrine therapy for the treatment of postmenopausal women with breast cancerExpert Rev Anticancer Ther20099218719819192957
   PubMed Web of Science ®Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative GroupLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• RiemsmaRForbesCAKesselsASystematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancerBreast Cancer Res Treat2010123192420535542
   PubMed Web of Science ®Google Scholar
• MaoCYangZYHeBFToremifene versus tamoxifen for advanced breast cancerCochrane Database Syst Rev20127CD00892622786516
   PubMed Web of Science ®Google Scholar
• MusgroveEASutherlandRLBiological determinants of endocrine resistance in breast cancerNat Rev Cancer20099963164319701242
   PubMed Web of Science ®Google Scholar
• DodwellDWardleyAJohnstonSPostmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitorsBreast200615558459416504510
   PubMed Web of Science ®Google Scholar
• OsborneCKSchiffRMechanisms of endocrine resistance in breast cancerAnnu Rev Med20116223324720887199
   PubMed Web of Science ®Google Scholar
• BarriosCForbesJFJonatWThe sequential use of endocrine treatment for advanced breast cancer: where are we?Ann Oncol20122361378138622317766
   PubMed Web of Science ®Google Scholar
• OakmanCMorettiESantarpiaLDi LeoAFulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancerFuture Oncol20117217318621345137
   PubMed Web of Science ®Google Scholar
• IngleJNSumanVJRowlandKMNorth Central Cancer Treatment Group Trial N0032Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032J Clin Oncol20062471052105616505423
   PubMed Web of Science ®Google Scholar
• PereyLParidaensRHawleHClinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)Ann Oncol2007181646917030543
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther2013301087088424158787
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA approves Afinitor for advanced breast cancer [press release]Silver Spring, MDUS Food and Drug Administration7202012 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htmAccessed December 18, 2013
   Google Scholar
• WilckenNDearRChemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007Eur J Cancer200844152218222518722111
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJExtending survival with chemotherapy in metastatic breast cancerOncologist200510Suppl 3202916368868
   PubMed Web of Science ®Google Scholar
• BinkleyJMHarrisSRLevangiePKPatient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancerCancer2012118Suppl 82207221622488695
   PubMed Web of Science ®Google Scholar
• Winters-StoneKMSchwartzALHayesSCFabianCJCampbellKLA prospective model of care for breast cancer rehabilitation: bone health and arthralgiasCancer2012118Suppl 82288229922488703
   PubMed Web of Science ®Google Scholar
• SantenRJClinical review: effect of endocrine therapies on bone in breast cancer patientsJ Clin Endocrinol Metab201196230831921147884
   PubMed Web of Science ®Google Scholar
• KanisJAMcCloskeyEVPowlesTPatersonAHAshleySSpectorTA high incidence of vertebral fracture in women with breast cancerBr J Cancer1999797–81179118110098755
   PubMed Web of Science ®Google Scholar
• LumachiFLuisettoGBassoSMBassoUBrunelloACamozziVEndocrine therapy of breast cancerCurr Med Chem201118451352221143113
   PubMed Web of Science ®Google Scholar
• AmirESerugaBNiraulaSCarlssonLOcañaAToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysisJ Natl Cancer Inst2011103171299130921743022
   PubMed Web of Science ®Google Scholar
• CroxtallJDMcKeageKFulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal womenDrugs201171336338021319872
   PubMed Web of Science ®Google Scholar
• HoeslyFJBakerSGGunawardaneNDCotliarJACapecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literatureArch Dermatol2011147121418142322184763
   PubMedGoogle Scholar
• GermanoSO’DriscollLBreast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicineCurr Cancer Drug Targets20099339841819442059
   PubMed Web of Science ®Google Scholar
• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
• LeeMCGrayJHanHSPloskerSFertility and reproductive considerations in premenopausal patients with breast cancerCancer Control201017316217220664513
   PubMed Web of Science ®Google Scholar
• Howard-AndersonJGanzPABowerJEStantonALQuality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic reviewJ Natl Cancer Inst2012104538640522271773
   PubMedGoogle Scholar
• MenesesKAzueroAHasseyLMcNeesPPisuMDoes economic burden influence quality of life in breast cancer survivors?Gynecol Oncol2012124343744322138013
   PubMed Web of Science ®Google Scholar
• Ashing-GiwaKTLimJWExploring the association between functional strain and emotional well-being among a population-based sample of breast cancer survivorsPsychooncology201019215015919253917
   PubMed Web of Science ®Google Scholar
• Heidari GorjiMABouzarZHaghshenasMKasaeeyanAASadeghiMRArdebilMDQuality of life and depression in caregivers of patients with breast cancerBMC Res Notes2012531022715918
   PubMedGoogle Scholar
• BremSKumarNBManagement of treatment-related symptoms in patients with breast cancerClin J Oncol Nurs2011151637121278042
   PubMed Web of Science ®Google Scholar
• SchmitzKHSpeckRMRyeSADiSipioTHayesSCPrevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through StudyCancer2012118Suppl 82217222522488696
   PubMed Web of Science ®Google Scholar
• BuijsCde VriesEGMouritsMJWillemsePHThe influence of endocrine treatments for breast cancer on health-related quality of lifeCancer Treat Rev200834764065518514425
   PubMed Web of Science ®Google Scholar
• BurrisHALebrunFRugoHSHealth-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialCancer2013119101908191523504821
   PubMed Web of Science ®Google Scholar
• EORTC Quality of Life GroupEORTC QLQ-C30 (version 3)BrusselsEORTC Quality of Life Group1995 Available from: http://groups.eortc.be/qol/sites/default/files/img/slider/specimen_qlq-c30_english.pdfAssessed December 18, 2013
   Google Scholar
• EORTC QLQ-BR23 [webpage on the Internet]BrusselsEORTC Quality of Life Group1994 Available from: http://groups.eortc.be/qol/sites/default/files/img/specimen_br-23_english.docAssessed December 18, 2013
   Google Scholar
• BarronJJQuimboRNikamPTAmonkarMMAssessing the economic burden of breast cancer in a US managed care populationBreast Cancer Res Treat2008109236737717674201
   PubMed Web of Science ®Google Scholar
• FuAZJhaveriMHealthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United StatesJ Med Econ201215468869422397589
   PubMedGoogle Scholar
• SorensenSVGohJWPanFIncidence-based cost-of-illness model for metastatic breast cancer in the United StatesInt J Technol Assess Health Care2012281122122617734
   PubMed Web of Science ®Google Scholar
• SchwartzbergLStreeterSBHussainNJohnsrudMAbandoning oral oncolytic prescriptions at the pharmacy: patient and health plan factors influencing adherencePoster presented at: Annual Meeting of the American Society of Clinical OncologyJune 3–7, 2011Chicago, IL, USA
   Google Scholar
• National Institute for Health and Care ExcellenceEverolimus in Combination with Exemestane for Treating Advanced HER2-Negative Hormone-Receptor-Positive Breast Cancer After Endocrine Therapy. NICE Technology Appraisal Guidance 295LondonNational Institute for Health and Care Excellence2013 Available from: http://www.nice.org.uk/nicemedia/live/14265/65061/65061.pdfAccessed December 18, 2013
   Google Scholar
• ChlebowskiRTGellerMLAdherence to endocrine therapy for breast cancerOncology2006711–21917344666
   PubMed Web of Science ®Google Scholar
• SedjoRLDevineSPredictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancerBreast Cancer Res Treat2011125119120020495864
   PubMed Web of Science ®Google Scholar
• WuJLuZKHormone therapy adherence and costs in women with breast cancerAm J Pharm Benefits2013526570
   Google Scholar
• SimonsWRJonesDBuzdarACost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancerClin Ther200325112972298714693319
   PubMed Web of Science ®Google Scholar
• DunnCKeamSJLetrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancerPharmacoeconomics200624549551716706574
   PubMed Web of Science ®Google Scholar
• CameronDACamidgeDROyeeJHirschMEconomic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancerBr J Cancer200899121984199019018261
   PubMed Web of Science ®Google Scholar
• ZeichnerSBRaja AvanchaKKVLopesGGluckSMonteroAJCost-effectiveness of everolimus plus exemestane in post-menopausal hormone receptor positive metastatic breast cancer [American Society of Clinical Oncology Annual Meeting abstract]J Clin Oncol201331Suppl 156548
   Web of Science ®Google Scholar
• XieJDienerMDeGYangHWuEQNamjoshiMBudget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United StatesJ Med Econ201316227828823153318
   PubMedGoogle Scholar
• GarreauJRDelamelenaTWaltsDKaramlouKJohnsonNSide effects of aromatase inhibitors versus tamoxifen: the patients’ perspectiveAm J Surg2006192449649816978958
   PubMed Web of Science ®Google Scholar